Locations
Columbus, OH, USA · Durham, NC, USA · North America
industry
Biotechnology · DeepTech · Health
Size
1 - 10 employees
Stage
Series A
founded in
2019
Basking Biosciences is focused on revolutionizing acute thrombosis treatment with its first-in-class reversible RNA aptamer, BB-031, designed to target von Willebrand Factor. The company aims to provide a safer and more effective therapy for acute ischemic stroke, with ongoing Phase II clinical trials demonstrating its commitment to addressing significant unmet medical needs. Founded on two decades of research, Basking's innovative approach leverages RNA aptamer technology to improve patient outcomes in acute revascularization therapy, positioning it as a leader in the cardiovascular therapeutic space.
Something looks off?